Search

Dane J Clausen

from Rahway, NJ
Age ~40
Get Report
Also known as:
Dane James Clausen, Dane R Clausen, Drake D Clausen
Phone and address:
991 W Lake Ave, Rahway, NJ 07065
Related to:
David Clausen Drake, 36Kristen K Clausen, 63Drake Clausen, 35Rosetta M Liggett, 36Kendall Clausen, 39Mark D Liggett, 71Rebecca A Clausen, 66Dana M Clausen, 39Lorraine A Liggett, 65Kinzie L Clausen, 33
Connected to:
Amanda M Clausen, 59Anna R Clausen, 42Beth E Clausen, 50Caroline Clausel, 66Colleen M Clausen, 76Dallas D Clausen, 80Dan W Clausen, 78Darlene S Clausen, 96Delynne C Clausen, 76Dylan C Clausen, 31

Dane Clausen Phones & Addresses

  • 991 W Lake Ave, Rahway, NJ 07065
  • Centennial, CO
  • Fort Collins, CO
  • Pittsburgh, PA
  • Boulder, CO
  • Broomfield, CO
  • 7591 S Emerson Cir, Centennial, CO 80122

Work

Company: Merck 2019 Position: Associate principal scientist, discovery chemistry

Education

School / High School: University of Pittsburgh 2019 to 2019 Specialities: Philosophy

Skills

Organic Chemistry • Organic Synthesis • Medicinal Chemistry • Nmr • Characterization • Mass Spectrometry • Lc Ms • Synthetic Organic Chemistry • Spectroscopy

Industries

Research

Resumes

Resumes

Dane Clausen Photo 1

Associate Principal Scientist, Discovery Chemistry

View page
Location:
991 west Lake Ave, Rahway, NJ 07065
Industry:
Research
Work:
Merck
Associate Principal Scientist, Discovery Chemistry
Merck 2014 - 2019
Senior Scientist, Discovery Chemistry
Colorado State University 2012 - 2014
Postdoctoral Fellow
University of Pittsburgh 2007 - 2012
Graduate Researcher
Array Biopharma Inc. 2005 - 2007
Assistant Chemist
Education:
University of Pittsburgh 2019 - 2019
University of Pittsburgh 2007 - 2012
University of Colorado Boulder 2003 - 2007
Bachelors, Bachelor of Arts, Biochemistry, Biology, Chemistry
Skills:
Organic Chemistry
Organic Synthesis
Medicinal Chemistry
Nmr
Characterization
Mass Spectrometry
Lc Ms
Synthetic Organic Chemistry
Spectroscopy

Publications

Us Patents

Heteroaryl Pyrrolidine And Piperidine Orexin Receptor Agonists

View page
US Patent:
20230018413, Jan 19, 2023
Filed:
Aug 3, 2020
Appl. No.:
17/632065
Inventors:
- Rahway NJ, US
Ping Chen - Edison NJ, US
Dane James Clausen - Rahway NJ, US
Jinsong Hao - Belle Mead NJ, US
Dipannita Kalyani - Union NJ, US
Michael T. Rudd - Collegeville PA, US
Shawn P. Walsh - Bridgewater NJ, US
Lan Wei - Berkeley Heights NJ, US
Dexi Yang - Livingston NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 403/04
C07D 207/14
C07D 401/04
C07D 471/04
C07D 417/04
C07D 413/10
C07D 417/14
C07D 413/04
C07D 409/04
C07D 405/04
C07D 498/04
C07D 491/048
Abstract:
The present invention is directed to heteroaryl pyrrolidine and piperidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Novel Substituted Piperazine Amide Compounds As Indoleamine 2,3-Dioxygenase (Ido) Inhibitors

View page
US Patent:
20230008022, Jan 12, 2023
Filed:
Nov 25, 2019
Appl. No.:
17/295497
Inventors:
Dane CLAUSEN - Kenilworth NJ, US
Ping CHEN - Kenilworth NJ, US
Xavier FRADERA - Boston MA, US
Liangqin GUO - Kenilworth NJ, US
Yongxin HAN - Boston MA, US
Shuwen HE - Fanwood NJ, US
Xianhai HUANG - Warren NJ, US
Joseph KOZLOWSKI - Princeton NJ, US
Guoqing LI - Kenilworth NJ, US
Theodore A. MARTINOT - Southborough MA, US
Alexander PASTERNAK - Boston MA, US
Andreas VERRAS - New York NY, US
Li XIAO - Kenilworth NJ, US
Wensheng YU - Kenilworth NJ, US
Rui ZHANG - Kenilworth NJ, US
- Rahway NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 231/56
C07D 491/052
C07D 231/54
A61K 31/496
C07D 401/12
C07D 401/14
C07D 413/12
A61K 31/5377
C07D 498/10
C07D 491/107
C07D 498/08
C07D 471/10
C07D 403/12
C07D 405/12
C07D 498/04
C07D 487/04
C07D 487/10
A61K 31/541
C07D 413/14
Abstract:
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Inhibitors Of Histone Deacetylase Useful For The Treatment Or Prevention Of Hiv Infection

View page
US Patent:
20210403479, Dec 30, 2021
Filed:
Nov 4, 2019
Appl. No.:
17/288626
Inventors:
- Rahway NJ, US
Joseph Kozlowski - Princeton NJ, US
Dane James Clausen - Rahway NJ, US
Jian Liu - Edison NJ, US
Younong Yu - East Brunswick NJ, US
Ming Wang - Belle Mead NJ, US
Bing Li - Towaco NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 487/10
C07D 403/12
C07D 413/14
C07D 401/14
C07D 401/12
C07D 471/04
C07D 417/14
C07D 498/10
C07D 405/14
A61K 45/06
Abstract:
The present invention relates to Compounds of Formula I: and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, R, Rand A are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I, and methods of using the compounds of Formula I for treating or preventing HIV infection in a subject.

Novel [1.1.1] Bicyclo Compounds As Indoleamine 2,3-Dioxygenase Inhibitors

View page
US Patent:
20210393600, Dec 23, 2021
Filed:
Apr 15, 2019
Appl. No.:
17/047247
Inventors:
- Rahway NJ, US
Hongjun Zhang - Boston MA, US
Ping Chen - Edison NJ, US
Dane Clausen - Rahway NJ, US
Xavier Fradera - Boston MA, US
Yongxin Han - Needham MA, US
Shuwen He - Fanwood NJ, US
Xianhai Huang - Warren NJ, US
Alexander Pasternak - Jamaica Plain MA, US
Qinglin Pu - Needham MA, US
Li Xiao - Cranbury NJ, US
Feng Ye - Scotch Plains NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
A61K 31/44
A61K 45/06
C07C 237/22
C07C 255/60
C07D 213/75
C07C 271/36
C07C 233/78
C07C 271/24
C07C 233/79
C07D 213/81
C07D 271/06
C07D 239/28
C07D 215/48
C07C 275/30
C07C 275/28
C07D 239/42
C07D 305/06
C07D 261/08
C07D 471/04
C07D 261/20
C07D 209/34
C07D 277/56
C07D 217/02
C07D 231/14
C07D 237/28
C07D 241/24
C07D 217/26
A61K 31/167
A61K 31/27
A61K 31/4245
A61K 31/47
A61K 31/17
A61K 31/505
A61K 31/337
A61K 31/437
A61K 31/42
A61K 31/426
A61K 31/472
A61K 31/415
A61K 31/4965
Abstract:
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Novel Substituted Pyrazole Compounds As Indoleamine 2,3-Dioxygenase Inhibitors

View page
US Patent:
20210395240, Dec 23, 2021
Filed:
Oct 28, 2019
Appl. No.:
17/287256
Inventors:
Dane CLAUSEN - Kenilworth NJ, US
- Rahway NJ, US
Liangqin Guo - Monroe Township NJ, US
Yongxin Han - Needham MA, US
Shuwen He - Fanwood NJ, US
Joseph Kozlowski - Princeton NJ, US
Guoqing Li - Belle Mead NJ, US
Theodore A. Martinot - Southborough MA, US
Alexander Pasternak - Jamaica Plain MA, US
David Sloman - Newton MA, US
Li Xiao - Cranbury NJ, US
Wensheng Yu - Edison NJ, US
Rui Zhang - Plainsboro NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 413/14
C07D 401/14
Abstract:
Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.

Inhibitors Of Histone Deacetylase Useful For The Treatment Or Prevention Of Hiv Infection

View page
US Patent:
20210276992, Sep 9, 2021
Filed:
Jul 26, 2019
Appl. No.:
17/261982
Inventors:
- Rahway NJ, US
Dane James Clausen - Rahway NJ, US
Wensheng Yu - Edison NJ, US
Joseph M. Kelly - Parlin NJ, US
Hyunjin M. Kim - Livingston NJ, US
Joseph A. Kozlowski - Princeton NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 413/14
C07D 417/14
C07D 471/04
C07D 413/12
C07D 498/10
C07D 487/04
C07D 498/04
C07D 513/04
Abstract:
The present invention relates to Compounds of Formula (I): Formula (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R, R, R, R, R, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula (I), and methods of using the compounds of Formula (I) for treating or preventing HIV infection in a subject.

5-Alkyl Pyrrolidine Orexin Receptor Agonists

View page
US Patent:
20200255403, Aug 13, 2020
Filed:
Feb 11, 2020
Appl. No.:
16/787201
Inventors:
- Rahway NJ, US
Dane James CLAUSEN - Rahway NJ, US
Deodial Guy GUIADEEN - Chesterfield NJ, US
Michael T. RUDD - Collegeville PA, US
Dexi YANG - Livingston NJ, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 401/14
C07D 207/16
C07D 409/12
C07D 403/12
Abstract:
The present invention is directed to 5-alkyl pyrrolidine compounds which are agonists of orexin receptors. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which orexin receptors are involved.

Novel Substituted Sulfoximine Compounds As Indoleamine 2,3-Dioxygenase (Ido) Inhibitors

View page
US Patent:
20200095212, Mar 26, 2020
Filed:
Feb 19, 2018
Appl. No.:
16/483957
Inventors:
- Rahway NJ, US
Dane Clausen - Rahway NJ, US
Liangqin Guo - Monroe Township NJ, US
Yongxin Han - Needham MA, US
Shuwen He - Fanwood NJ, US
Joseph Kozlowski - Princeton NJ, US
Derun Li - West Roxbury MA, US
Qinglin Pu - Needham MA, US
Wensheng Yu - Edison NJ, US
Hongjun Zhang - Boston MA, US
Assignee:
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
C07D 271/08
C07D 413/12
Abstract:
Compounds of Formula I, or a pharmaceutically acceptable salt, solvate or hydrate thereof: (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.
Control profile
Dane J Clausen from Rahway, NJ, age ~40 Get Report